Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-28T08:40:56.918Z Has data issue: false hasContentIssue false
  • English
  • Français

The Antibiotic Development Pipeline for Multidrug-Resistant Gram-Negative Bacilli: Current and Future Landscapes

Published online by Cambridge University Press:  02 January 2015

George H. Talbot
George H. Talbot*
Affiliation:
Talbot Advisors LLC, Wayne, Pennsylvania
*
PO Box 7440, St. Davids, PA 19087 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Development of antibiotics to treat infections caused by multidrug-resistant gram-negative bacilli has lagged significantly behind development of antibiotics to treat infections with gram-positive pathogens. Although a few promising drugs have entered early clinical development, more must be done to preserve the utility of currently available antibiotics and to ensure a pipeline of efficacious, safe antibacterials.

Type
Supplement Article
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue S1: Papers from the Fifth Decennial International Conference on Healthcare-Associated Infections , November 2010 , pp. S55 - S58
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kallen, AJ, Srinivasan, A. Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 2010;31(11 Suppl 1):S51–S54 (in this supplement).CrossRefGoogle ScholarPubMed
2.Boucher, HW, Talbot, GH, Bradley, JS, et al.Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1–12.CrossRefGoogle ScholarPubMed
3.European Centre for Disease Prevention and Control (ECDC); European Medicines Agency (EMEA). The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. Stockholm: European Centre for Disease Prevention and Control, 2009. http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed March 19, 2010.Google Scholar
4.Talbot, GH. What's in the pipeline for gram-negative pathogens? Expert Rev Anti Infect Ther 2008;6(1):39–49.CrossRefGoogle Scholar
5. Achaogen. http://www.achaogen.com/. Accessed April 18, 2010.Google Scholar
6. Novexel. Mature and diverse pipeline, http://www.novexel.com/contenu.php?page = pipeline. Accessed April 18, 2010.Google Scholar
7.Ge, Y, Biek, D, Talbot, GH, Sahm, DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimcrob Agents Chemother 2008;52(9):3398–3407.CrossRefGoogle ScholarPubMed
8.Brown, NP, Pillar, CM, Sahm, DF, Ge, Y. Activity profile of CXA-101 and CXA-101/tazobactam against target gram-positive and gram-negative pathogens. In: Program and abstracts of the 49th Interscience Conference of Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA. Abstract F1-1986.Google Scholar
9. Cubist Pharmaceuticals. Our advancing pipeline, http://www.cubist.com/products/index.php#pipeline. Accessed March 19, 2010.Google Scholar
10. Basilea Pharmaceutica. Anti-infectives research: overview. http://www.basilea.com/Research/Anti-infectives-research/. Accessed April 17, 2010.Google Scholar
11.Infectious Diseases Society of America. The 10 × ‘20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50(8):1081–1083.CrossRefGoogle Scholar